Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences

References

• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31
   PubMed Web of Science ®Google Scholar
• Best, L, Simmonds, P, Baughan, C, Buchanan, R, Davis, C, Fentiman, I, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration. Cochrane Database Syst Rev 2000;CD001545.
   Google Scholar
• Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004; 100: 1558–77
   PubMed Web of Science ®Google Scholar
• Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 1997; 44: 535–9
   PubMed Web of Science ®Google Scholar
• Vercelli M, Quaglia A, Casella C, Parodi S, Capocaccia R, Martinez GC. Relative survival in elderly cancer patients in Europe. Eur J Cancer 1998; 34: 2264–70
   PubMed Web of Science ®Google Scholar
• Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001; 12: 435–42
   PubMed Web of Science ®Google Scholar
• Jessup JM, McGinnis LS, Steele GD, Jr, Menck HR, Winchester DP. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78: 918–26
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061–7
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91
   PubMed Web of Science ®Google Scholar
• Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759–66
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190–7
   PubMed Web of Science ®Google Scholar
• Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–75
   PubMed Web of Science ®Google Scholar
• Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279–87
   PubMed Web of Science ®Google Scholar
• Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20: 3–10
   PubMed Web of Science ®Google Scholar
• Gatta G, Faivre J, Capocaccia R, Ponz DL. Survival of colorectal cancer patients in Europe during the period 1978–1989. EUROCARE Working Group. Eur J Cancer 1998; 34: 2176–83
   PubMed Web of Science ®Google Scholar
• Specht LK, Landberg T. Cancer treatment in Skane and in Sjaelland. Do differences concerning examination and treatment explain reduced survival among Danish cancer patients?. Ugeskr Laeger 2001; 163: 439–42
   PubMedGoogle Scholar
• Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412–8
   PubMed Web of Science ®Google Scholar
• Cooper GS, Yuan Z, Landefeld CS, Johanson JF, Rimm AA. A national population-based study of incidence of colorectal cancer and age. Implications for screening in older Americans. Cancer 1995; 75: 775–81
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391–9
   PubMed Web of Science ®Google Scholar
• Iversen, LH, Pedersen, L, Riis, A, Friis, S, Laurberg, S, Sorensen, HT. Age and Colorectal Cancer with focus on the elderly: trends in relative survival and initial treatment from a Danish population-based study. Dis Colon Rectum 2005.
   PubMedGoogle Scholar
• McCusker J, Wax A, Bennett JM. Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry. Am J Clin Oncol 1982; 5: 227–36
   PubMedGoogle Scholar
• Penman DT, Holland JC, Bahna GF, Morrow G, Schmale AH, Derogatis LR, et al. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol 1984; 2: 849–55
   PubMed Web of Science ®Google Scholar
• Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94: 2766–92
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 2003; 42: 832–6
   PubMed Web of Science ®Google Scholar